Alternative hepatitis B virus DNA confirmatory algorithm identified occult hepatitis B virus infection in Chinese blood donors with non-discriminatory nucleic acid testing.
Journal
Blood transfusion = Trasfusione del sangue
ISSN: 2385-2070
Titre abrégé: Blood Transfus
Pays: Italy
ID NLM: 101237479
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
30
06
2020
accepted:
17
09
2020
pubmed:
29
12
2020
medline:
3
5
2022
entrez:
28
12
2020
Statut:
ppublish
Résumé
Multiplex viral nucleic acid testing (NAT) and a discriminatory testing algorithm have been used to detect viral infections in blood donors. Non-discriminated reactive (NDR) results may arise from low hepatitis B virus (HBV) DNA levels and are challenging for donor management by blood services. The aim of this study was to evaluate the performance and feasibility of alternative viral particle concentration methods to confirm and to characterise HBV infection status in NDR donors from Dalian, China, in order to improve routine donor management according to the potential residual risk estimate. Individual donations were tested with ULTRIO Plus, and discriminated when reactive. Virions were concentrated from 12 and 6 mL plasma samples by ultracentrifugation (UC) and polyethylene glycol (PEG) precipitation, respectively. HBV DNA was detected with four nested polymerase chain reactions (95% limit of detection: 5-25 IU/mL). Amplified products were sequenced for definitive confirmation. Anti-HBc and anti-HBs were tested. Of 77,556 donors, 79 (0.1%) were NAT NDR. After viral particle concentration by UC and PEG precipitation, HBV DNA was detected in 46 (58.2%) and 34 (43.0%) NDR donors, respectively, including 61.7% of samples that were repeatedly non-reactive with multiple NAT testing. Anti-HBc and anti-HBs (median titre: 37 mIU/mL) were detected in 87.3% and 46.8% of NDR donors, respectively. Sequencing confirmed HBV DNA in 65.8% of NDR donors, of whom 96.2% were occult HBV carriers with rare mutations in S and core proteins. A HBV DNA confirmatory procedure with limited technical constraints was implemented successfully. The majority of NDR donors had occult HBV infections with extremely low viral DNA levels, which may constitute a potential residual threat for blood safety. Only a minority of anti-HBc+ NDR donors had anti-HBs levels high enough to consider their reinstatement as donors. The data support the permanent deferral of NDR donors to ensure maximum blood safety in areas of high HBV endemicity.
Sections du résumé
BACKGROUND
Multiplex viral nucleic acid testing (NAT) and a discriminatory testing algorithm have been used to detect viral infections in blood donors. Non-discriminated reactive (NDR) results may arise from low hepatitis B virus (HBV) DNA levels and are challenging for donor management by blood services. The aim of this study was to evaluate the performance and feasibility of alternative viral particle concentration methods to confirm and to characterise HBV infection status in NDR donors from Dalian, China, in order to improve routine donor management according to the potential residual risk estimate.
MATERIALS AND METHODS
Individual donations were tested with ULTRIO Plus, and discriminated when reactive. Virions were concentrated from 12 and 6 mL plasma samples by ultracentrifugation (UC) and polyethylene glycol (PEG) precipitation, respectively. HBV DNA was detected with four nested polymerase chain reactions (95% limit of detection: 5-25 IU/mL). Amplified products were sequenced for definitive confirmation. Anti-HBc and anti-HBs were tested.
RESULTS
Of 77,556 donors, 79 (0.1%) were NAT NDR. After viral particle concentration by UC and PEG precipitation, HBV DNA was detected in 46 (58.2%) and 34 (43.0%) NDR donors, respectively, including 61.7% of samples that were repeatedly non-reactive with multiple NAT testing. Anti-HBc and anti-HBs (median titre: 37 mIU/mL) were detected in 87.3% and 46.8% of NDR donors, respectively. Sequencing confirmed HBV DNA in 65.8% of NDR donors, of whom 96.2% were occult HBV carriers with rare mutations in S and core proteins.
DISCUSSION
A HBV DNA confirmatory procedure with limited technical constraints was implemented successfully. The majority of NDR donors had occult HBV infections with extremely low viral DNA levels, which may constitute a potential residual threat for blood safety. Only a minority of anti-HBc+ NDR donors had anti-HBs levels high enough to consider their reinstatement as donors. The data support the permanent deferral of NDR donors to ensure maximum blood safety in areas of high HBV endemicity.
Identifiants
pubmed: 33370226
pii: 2020.0213-20
doi: 10.2450/2020.0213-20
pmc: PMC8796838
doi:
Substances chimiques
DNA, Viral
0
Hepatitis B Antibodies
0
Hepatitis B Core Antigens
0
Hepatitis B Surface Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8-17Références
Blood Transfus. 2017 Jan;15(1):6-12
pubmed: 27416568
Transfusion. 2014 Aug;54(8):2084-91
pubmed: 24650170
Blood Transfus. 2009 Jul;7(3):174-82
pubmed: 19657480
J Viral Hepat. 2012 Oct;19(10):716-23
pubmed: 22967103
Transfusion. 2013 Jul;53(7):1405-15
pubmed: 23362802
Transfusion. 2019 Aug;59(8):2602-2611
pubmed: 31168835
Gut. 2019 Feb;68(2):313-321
pubmed: 29959168
J Hepatol. 2012 Oct;57(4):720-9
pubmed: 22634131
J Virol. 2013 Jul;87(14):7882-92
pubmed: 23658444
Transfusion. 2017 Mar;57(3pt2):832-840
pubmed: 28164313
Transfusion. 2014 Oct;54(10):2485-95
pubmed: 24738835
BMC Infect Dis. 2019 Jul 3;19(1):574
pubmed: 31269905
Transfusion. 2015 Feb;55(2):395-404
pubmed: 25125223
Vox Sang. 2013 Feb;104(2):93-9
pubmed: 22924987
J Hepatol. 2019 Aug;71(2):397-408
pubmed: 31004683
Transfusion. 2020 Feb;60(2):334-342
pubmed: 31909495
Emerg Microbes Infect. 2019;8(1):1337-1346
pubmed: 31516090
Vox Sang. 2015 Feb;108(2):113-22
pubmed: 25234417
Vox Sang. 2013 Jan;104(1):7-11
pubmed: 22765287
Vox Sang. 2018 Jul 4;:
pubmed: 29974475
Front Med (Lausanne). 2018 Feb 21;5:29
pubmed: 29515997
Transfusion. 2016 Feb;56(2):457-65
pubmed: 26509432
Transfusion. 2015 Sep;55(9):2272-81
pubmed: 26177670
Transfusion. 2013 Oct;53(10 Pt 2):2477-88
pubmed: 23521050
J Virol. 2009 Nov;83(22):11616-23
pubmed: 19710138
Virus Res. 2018 Sep 15;257:33-39
pubmed: 30179704
Vox Sang. 2017 Oct;112(7):622-627
pubmed: 28891069
Transfusion. 2009 Jun;49(6):1115-25
pubmed: 19309474
J Virol. 2002 Jul;76(13):6510-7
pubmed: 12050364
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32669381
Transfusion. 2013 Oct;53(10 Pt 2):2512-24
pubmed: 23590145
N Engl J Med. 2011 Jan 20;364(3):236-47
pubmed: 21247314
Transfusion. 2017 Jan;57(1):24-35
pubmed: 27673757
Gut. 2012 Dec;61(12):1744-53
pubmed: 22267593